Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?Giovanna Garufi, Fabio Puglisi, Antonella Palazzo et al.|Cancer Treatment Reviews|2022Cited by 20
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Emilio Bria, Luisa Carbognin et al.|Therapeutic Advances in Medical Oncology|2023Cited by 11
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Emilio Bria, Giovanna Garufi et al.|npj Breast Cancer|2025Cited by 9
Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant ChemotherapyGiovanna Garufi, Emilio Bria, Luca Mastrantoni et al.|Research Square|2024Cited by 0